

37. Burgos AM and Saver JL. Evidence that tenecteplase is non-inferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. *Stroke* 2019; 50: 2156–2162.
38. Nepal G, Kharel G, Ahamad ST, et al. Tenecteplase versus alteplase for the management of acute ischemic stroke in a low-income Country–Nepal: cost, efficacy, and safety. *Cureus* 2018; 10: e2178.
39. Beharry J, Waters MJ, Drew R, et al. Dabigatran reversal before intravenous tenecteplase in acute ischemic stroke. *Stroke* 2020; 51: 1616–1619.
40. Mahawish K, Gommans J, Kleinig T, et al. Switching to tenecteplase for stroke thrombolysis: real-world experience and outcomes in a regional stroke network. *Stroke* 2021; 52: e590–e593.
41. Zhong CS, Beharry J, Salazar D, et al. Routine use of tenecteplase for thrombolysis in acute ischemic stroke. *Stroke* 2021; 52: 1087–1090.
42. Psychogios K, Palaodimou L, Katsanos AH, et al. Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion. *Ther Adv Neurol Disord* 2021; 14: 1756286420986727.
43. Gerschenfeld G, Smadja D, Turc G, et al.; TETRIS Study Group. Functional outcome, recanalization, and hemorrhage rates after large vessel occlusion stroke treated with tenecteplase before thrombectomy. *Neurology* 2021; 97: e2173–e2184.
44. Alemseged F, Ng FC, Williams C, et al.; BATMAN study group and EXTEND IA TNK study group. Tenecteplase vs alteplase before endovascular therapy in basilar artery occlusion. *Neurology* 2021; 96: e1272–e1277.
45. Tsvigoulis G, Katsanos AH, Christogiannis C, et al. Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke. *Ann Neurol* 2022; 92: 349–357.
46. Katsanos AH, Psychogios K, Turc G, et al. Off-Label use of tenecteplase for the treatment of acute ischemic stroke: A systematic review and meta-analysis. *JAMA Netw Open* 2022; 5: e224506.
47. Kheiri B, Osman M, Abdalla A, et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. *J Thromb Thrombolysis* 2018; 46: 440–450.
48. Jacob AP, Parker SA, Bowry R, et al. How frequent is the one-hour tPA infusion interrupted or delayed? *J Stroke Cerebrovasc Dis* 2022; 31: 106471.
49. Bivard A, Huang X, Levi CR, et al. Tenecteplase in ischemic stroke offers improved recanalization: analysis of 2 trials. *Neurology* 2017; 89: 62–67.
50. Roaldsen MB, Lindekleiv H, Eltoft A, et al. Tenecteplase in wake-up ischemic stroke trial: protocol for a randomized-controlled trial. *Int J Stroke* 2021; 16: 990–994.
51. Ahmed HK, Logallo N, Thomassen L, et al. Clinical outcomes and safety profile of tenecteplase in wake-up stroke. *Acta Neurol Scand* 2020; 142: 475–479.
52. Marshall RS. Progress in intravenous thrombolytic therapy for acute stroke. *JAMA Neurol* 2015; 72: 928–934.
53. Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. *Clin Pharmacokinet* 2002; 41: 1229–1245.
54. Putaala J, Saver JL, Nour M, et al. Should tenecteplase be given in clinical practice for acute ischemic stroke thrombolysis? *Stroke* 2021; 52: 3075–3080.
55. Safouris A, Magoufis G and Tsvigoulis G. Emerging agents for the treatment and prevention of stroke: progress in clinical trials. *Expert Opin Investig Drugs* 2021; 30: 1025–1035.